Hemrajani Rekha
SEC-identified person · CIK 1771213 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Maxcyte, INC. MXCT | Director | filed 2021 - 2026 |
| Bioage Labs, Inc. BIOA | Director | filed 2024 - 2026 |
| LB Pharmaceuticals INC LBRX | Director | filed 2025 - 2026 |
| ALX Oncology Holdings INC ALXO | Director | filed 2020 - 2026 |
| Jiya Acquisition Corp. JYAC | Director · Chief Executive Officer | filed 2020 - 2020 |
| Avalanche Biotechnologies, Inc. [AAVL] | Director | filed 2019 - 2020 |
| Versartis, Inc. VSAR | Director · President and CEO | filed 2020 - 2020 |
| Arcus Biosciences, Inc. RCUS | See Remarks | filed 2019 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.